Ocrevus (ocrelizumab) / Roche, Biogen - LARVOL DELTA

Developing anti-CD20 molecules and B cell depletion in multiple sclerosis (PubMed, Ideggyogy Sz) - "Since then, three anti-CD20 monoclonal antibodies - ocrelizumab, ofatumumab, and ublituximab - have been developed and approved for MS treatment, whereas rituximab, the first monoclonal antibody shown to be effective, remains an off-label therapy in this indication...Fc engineering can enhance ADCC and partially overcome the functional consequences of FcγRIIIa polymorphisms. This article reviews the structure and mechanisms of action of immunoglobulins and anti-CD20 antibodies; outlines the development of antibody humanization and Fc engineering to enhance efficacy and tolerability; presents clinical data from ublituximab treatment; and discusses additional strategies for achieving effective B-cell depletion."

Journal • Review • CNS Disorders • Multiple Sclerosis

Optical Coherence Tomography Angiography Findings in Primary Progressive Multiple Sclerosis Patients Receiving Ocrelizumab Treatment. (PubMed, Diagnostics (Basel)) - "The mean FAZ area was also statistically different between the subgroups. The findings suggest that macular superficial and deep vascular densities are affected in PPMS patients receiving the same therapy modality and that previous optic neuritis may influence the results."

Journal • CNS Disorders • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Ocular toxicity associated with anti-CD20 monoclonal antibodies: A pharmacovigilance analysis using the FAERS database. (PubMed, Mult Scler Relat Disord) - "Anti-CD20 antibodies require careful ocular monitoring, particularly in multiple sclerosis patients. The elevated blepharospasm risks with ofatumumab and dyschromatopsia with rituximab highlights potential CNS-and optic pathway-related effects that warrant further study to improve MS treatment safety."

Adverse events • Journal • CNS Disorders • Hematological Malignancies • Immunology • Infectious Disease • Multiple Sclerosis • Ocular Infections • Oncology • Ophthalmology • ROR1

OCREFINA: Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis (clinicaltrials.gov) - P4 | N=5 | Enrolling by invitation | Sponsor: University of California, San Francisco | Recruiting ➔ Enrolling by invitation | Trial completion date: Dec 2025 ➔ Jun 2027 | Trial primary completion date: Dec 2025 ➔ Jun 2027

Enrollment status • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

MMR SEROLOGIC STATUS IN MULTIPLE SCLEROSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (EBMT 2026) - "Background: Multiple sclerosis (MS) patients undergoing autologous stem cell transplantation (ASCT) after carmustine, cytarabine, etoposide, melphalan (BEAM) or cyclophosphamide (Cy) chemotherapy plus rabbit anti-thymocyte globulin (rATG) are considered as naïve to vaccines and offered revaccination; live vaccines as measles/mumps/rubella (MMR) are not recommended before 24 months from ASCT with concern about vaccine-induced infectious disease...The two patients who lost either MMR (ID23) or rubella immunity (ID35) had both low titles at baseline; prior to ASCT, they had received interferon and 3 lines of therapy (interferon, fingolimod, ocrelizumab), respectively... In our real-life population of ASCT-treated MS, the vast majority of patients retained MMR immunity with a slight decline of vaccine titres over time confirming that MMR revaccination could be safely postponed after 24 months from ASCT and probably offered only in selected patients at high risk (i.e...."

CNS Disorders • Infectious Disease • Measles • Multiple Sclerosis • Mumps • Rubella • Transplantation

MMR SEROLOGIC STATUS IN MULTIPLE SCLEROSIS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (EBMT 2026) - "Background: Multiple sclerosis (MS) patients undergoing autologous stem cell transplantation (ASCT) after carmustine, cytarabine, etoposide, melphalan (BEAM) or cyclophosphamide (Cy) chemotherapy plus rabbit anti-thymocyte globulin (rATG) are considered as naïve to vaccines and offered revaccination; live vaccines as measles/mumps/rubella (MMR) are not recommended before 24 months from ASCT with concern about vaccine-induced infectious disease...The two patients who lost either MMR (ID23) or rubella immunity (ID35) had both low titles at baseline; prior to ASCT, they had received interferon and 3 lines of therapy (interferon, fingolimod, ocrelizumab), respectively... In our real-life population of ASCT-treated MS, the vast majority of patients retained MMR immunity with a slight decline of vaccine titres over time confirming that MMR revaccination could be safely postponed after 24 months from ASCT and probably offered only in selected patients at high risk (i.e...."

CNS Disorders • Infectious Disease • Measles • Multiple Sclerosis • Mumps • Rubella • Transplantation

Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysis. (PubMed, Ther Adv Neurol Disord) - "B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS)...Topical therapies were effective in most cases, but a change of MS treatment or initiation of psoriasis-specific immunotherapies, including the interleukin-17A-antibody secukinumab, was required in four patients...While most cases are manageable with standard psoriasis treatments, severe cases may necessitate therapy adjustments. The potential immunological interplay between MS and psoriasis treatment warrants further investigation."

Journal • Retrospective data • CNS Disorders • Dermatology • Immunology • Multiple Sclerosis • Psoriasis • IL17A

21-PP-23: LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB IN FRENCH PATIENTS WITH PROGRESSIVE MS: CONSONANCE EXTENSION STUDY (clinicaltrialsregister.eu) - P2/3 | N=89 | Recruiting | Sponsor: Centre Hospitalier Universitaire De Nice | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Multiple Sclerosis

Seronegative secondary syphilis in a patient treated with ocrelizumab for multiple sclerosis. (PubMed, Eur J Dermatol) - No abstract available

Journal • CNS Disorders • Infectious Disease • Multiple Sclerosis

Paroxysmal motor signs in multiple sclerosis: an illustrative videotaped case. (PubMed, Oxf Med Case Reports) - "The dystonic movements resolved with corticosteroid therapy, while symptomatic management with carbamazepine was required for dysarthria-ataxia. Ocrelizumab has been proposed as a long-term disease-modifying treatment. This case highlights the importance of recognizing paroxysmal motor signs in MS for early diagnosis and tailored management, despite their elusive pathogenesis."

Journal • Ataxia • CNS Disorders • Dystonia • Movement Disorders • Multiple Sclerosis

Ocrelizumab Discontinuation vs. Continuation After Safety Events: Comparative Insights from MSBase. (PubMed, Curr Neuropharmacol) - "In this propensity-score-matched analysis, OCR discontinuation due to safety concerns was associated with increased relapse activity and trends toward greater disability progression. These findings highlight the importance of maintaining therapeutic intensity and systematic monitoring during treatment transitions to mitigate safety risks Further research is needed to develop strategies for effectively managing adverse events to optimize patient outcomes."

Journal • CNS Disorders • Multiple Sclerosis • CD20

Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series. (PubMed, Front Immunol) - "At last follow-up, adverse reactions had completely improved in 4/13, incompletely improved in 6/13, and persisted in 3/13 patients. Clinicians should be aware of dermatological and gastrointestinal adverse reactions associated with ocrelizumab, which can develop from a few weeks up to six years after start of therapy."

Journal • Retrospective data • CNS Disorders • Crohn's disease • Dermatology • Dermatopathology • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Lichen Planus • Multiple Sclerosis • Psoriasis • Psoriatic Arthritis • Rheumatology • Rosacea • Seronegative Spondyloarthropathies

Advancements in Pharmacotherapy and Mobile Health Applications for Self-Management in Multiple Sclerosis: A Comprehensive Review. (PubMed, Recent Pat Biotechnol) - "Monoclonal antibodies define the upper limit of efficacy in current MS therapy, but sustainability depends on safety oversight and patient engagement. Oral formulations remain clinically pragmatic first-line options. The synergy between pharmacotherapy and mobile health technology offers a pathway to transform adherence, monitoring, and outcome optimization in future MS management."

Journal • CNS Disorders • Immunology • Infectious Disease • Multiple Sclerosis

Neutropenia after ocrelizumab treatment in patients with multiple sclerosis: A single-centre case series and systematic review of literature. (PubMed, Mult Scler Relat Disord) - "Neutropenia occurred early in treatment. Most patients presented with high-grade neutropenia but experienced a mild clinical course. Ocrelizumab resumption was possible. Recurrence may happen in the same or following cycles."

Journal • Review • CNS Disorders • Hematological Disorders • Multiple Sclerosis • Neutropenia

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Hoffmann-La Roche

New P4 trial • CNS Disorders • Multiple Sclerosis

Ocrelizumab-induced acute pancreatitis: case report of an uncommon side effect of multiple sclerosis treatment. (PubMed, Int J Surg Case Rep) - "His medications included carbamazepine (commenced 5 years earlier without prior pancreatitis) and folic acid. Pancreatitis should be considered in ocrelizumab-treated patients presenting with abdominal pain, even when routine risk factors are absent. Early recognition enables appropriate management and contributes to a growing evidence base needed to clarify pathophysiology and refine risk stratification for this uncommon adverse event."

Adverse events • Journal • CNS Disorders • Dyslipidemia • Gastroenterology • Hypertriglyceridemia • Inflammation • Multiple Sclerosis • Pain • Pancreatitis

Obinutuzumab (Gazyva) for lupus nephritis. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis (clinicaltrials.gov) - P3 | N=126 | Recruiting | Sponsor: Sandoz | N=87 ➔ 126

Enrollment change • CNS Disorders • Multiple Sclerosis

Central Nervous System Demyelination Associated with TNF-Alpha inhibitors: A 20-Year Systematic Review (ACTRIMS Forum 2026) - "Certolizumab showed the earliest onset (mean 8.7 months, SD 13.2), adalimumab (mean 17.7, SD 16.3), etanercept (mean 22.5, SD 34.7), Infliximab (mean 27.7, SD 17.0), & golimumab (mean 32.2, SD 56.0)...For the neurological disorder, only 17.4% of patients required long-term management with disease-modifying therapy, most commonly rituximab (26%), ocrelizumab (15%), and glatiramer with interferon combination (15%)...Following TNF-alpha-inhibitor cessation, 29.03% experienced worsening of their systemic autoimmune condition & 9.6 % required alternative biological therapy, commonly secukinumab, ustekinumab, tocilizumab, or methotrexate... TNF-α inhibitors, though effective for autoimmune diseases, may unpredictably be associated with CNS demyelination. Most often linked with adalimumab, etanercept, and infliximab. While many patients recover after discontinuing steroids, some have persistent deficits, underscoring the need for cautious use and close neurological..."

Review • CNS Disorders • Immunology • Multiple Sclerosis • Ocular Inflammation • Ophthalmology • Optic Neuritis

Ocrelizumab in a difficult-to-treat rheumatoid arthritis patient. (PubMed, Clin Exp Rheumatol) - No abstract available

Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

The Exit Strategy: Clinical Outcomes and Safety of De-escalating High-efficacy Therapies in Multiple Sclerosis (AAN 2026) - ""Stable" PwMS transitioned from natalizumab (50%), ocrelizumab (49%) or alemtuzumab (1%). Most PwMS were de-escalated to cladribine (49%) or a fumarate (41%)... These findings suggest that age may be an influential factor in determining stability after de-escalation and de-escalation from ocrelizumab appears to be safer than from natalizumab. Therefore, the decision to de-escalate should be based on individual patients' characteristics."

Clinical • Clinical data • CNS Disorders • Multiple Sclerosis

Urinary Tract Infections and Urosepsis in Multiple Sclerosis: Insights from FDA Pharmacovigilance Data (AAN 2026) - "Ocrelizumab had the greatest association with UTI, and natalizumab, alemtuzumab, and interferon-beta-1a exhibited safety signals for both outcomes across all sex and age subgroups. This real-world pharmacovigilance analysis identifies disproportionate reporting of UTI and urosepsis across several MS DMTs, underscoring their contribution to morbidity and mortality. These associations likely reflect both therapy-related immunologic effects and disease-intrinsic factors, particularly neurogenic bladder dysfunction. These findings highlight the need for vigilant infection surveillance, proactive bladder management, and individualized risk assessment in MS care."

Adverse events • CNS Disorders • Immunology • Infectious Disease • Multiple Sclerosis • Nephrology • Urology

Emgality Transfer into Breast Milk (AAN 2026) - "Monoclonal antibodies used in other neurological conditions (such as rituximab, ocrelizumab) have previously shown low transfer into breast milk. An oral CGRP receptor antagonist, rimegepant, has a low RID in human breast milk; until this study, no published data were available on the transfer of galcanezumab, an injectable CGRP monoclonal antibody, into human breast milk. Understanding the transfer into breast milk of highly effective migraine therapies such as galcanezumab is crucial to providing women safe, effective treatments for headaches, especially during the postpartum period when at high risk of migraine recrudescence."

CNS Disorders • Migraine

Appendicitis and multiple sclerosis disease-modifying therapies: a disproportionality analysis of the FDA adverse event reporting system. (PubMed, Mult Scler Relat Disord) - "Patient counseling on early appendicitis warning signs and indications for urgent evaluation may be warranted for people with MS on DMTs."

Adverse events • Journal • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Multiple Sclerosis

Priced out of Progress: Neurology Innovation Beyond Patient Reach (AAN 2026) - "In South Asian LMICs, their entry has been delayed, and prices far exceed median household income, limiting accessibility and clinical integration.Design/ We audited six therapies (ocrelizumab, risdiplam, onasemnogene abeparvovec, lecanemab, donanemab, tenecteplase)... Recent neurological breakthroughs remain inaccessible for most LMIC patients. When present, therapies are limited to a few tertiary hospitals and remain unaffordable relative to household means. Closing this gap requires LMIC-specific reforms: pooled procurement, tiered pricing, subsidy schemes for time-critical drugs, and hub-and-spoke expansion neurological services."

Clinical • Cardiovascular